🇺🇸 FDA
Pipeline program

Sumatriptan succinate

PROT-15-NP101-011

Phase 1 small_molecule completed

Quick answer

Sumatriptan succinate for Migraine Disorders is a Phase 1 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Migraine Disorders
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials